Cervical intraepithelial neoplasia and higher long term risk of cancerBMJ 2007; 335 doi: https://doi.org/10.1136/bmj.39364.439444.80 (Published 22 November 2007) Cite this as: BMJ 2007;335:1053
- Guglielmo Ronco, responsible for cervical screening evaluation unit1,
- Mario Giovanni Sideri, director2,
- Stefano Ciatto, director3
- 1Unit of Cancer Epidemiology, Centre for Cancer Prevention, 10123 Torino, Italy
- 2Preventive Gynaecology Unit, European Institute of Oncology, 20141 Milan, Italy
- 3Department of Diagnostic Imaging, Scientific Institute for Cancer Prevention of Tuscany Region, 50131 Florence, Italy
In some countries, such as the United Kingdom, women have long term intensive surveillance after conservative treatment for high grade cervical intraepithelial neoplasia, whereas in others, such as the Netherlands and Finland, they return to regular screening after a few years. The second choice is based on the consistent observation that most recurrences of cervical intraepithelial neoplasia occur in the first two to three years after treatment.1
In this week's BMJ, Strander and colleagues provide strong evidence that women treated for cervical intraepithelial neoplasia grade 3 have a long lasting excess risk of invasive cervical cancer.2 Among more than 130 000 women with this condition, the age adjusted incidence was more than double that of the general population up to 20-25 years after diagnosis. The excess incidence was greater in women treated at older age and in recent years.
How do these findings translate into clinical recommendations? The important question is how different follow-up schedules compare in terms of effectiveness and cost in preventing the excess …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial